What a PDUFA Date Actually Is
The Prescription Drug User Fee Act requires the FDA to review New Drug Applications (NDAs) and Biologics License Applications (BLAs) within a set timeframe — typically 10 months for standard review, 6 months for priority review. The PDUFA date is the FDA’s self-imposed deadline to complete that review.
It is not a guaranteed approval date. The FDA must act — approve, issue a Complete Response Letter (CRL) denying approval, or request an extension. In practice, the FDA acts on or before the PDUFA date in the vast majority of cases.
For traders: PDUFA dates are known in advance, represent binary outcomes, and move stocks dramatically. That combination makes them one of the few genuinely high-probability setup opportunities in any market.
How Binary Are PDUFA Outcomes?
Very. A single FDA decision can send a stock up 50-200% on approval or destroy 40-80% of market cap on a CRL. Historical approval rates for drugs reaching PDUFA review run around 85-90% — but that aggregate is misleading. Drugs with prior FDA concerns, failed Phase 3 endpoints, or negative Advisory Committee votes have dramatically lower individual probabilities. Context is everything.
The Full PDUFA Catalyst Sequence
1. NDA/BLA Acceptance (+60 Days)
When the FDA accepts an application for review, it confirms the filing is complete and sets the PDUFA date. Acceptance removes meaningful uncertainty. A Refuse to File (RTF) action here is a serious red flag.
2. Advisory Committee Meeting (AdCom)
For many drugs, the FDA convenes an external expert panel that votes on whether the drug should be approved. AdCom votes are non-binding, but the FDA follows them roughly 75-80% of the time. A positive AdCom vote dramatically increases approval probability. A negative vote is frequently fatal to the application.
3. The PDUFA Date Decision
Decisions typically arrive in the morning hours on or before the PDUFA date. The stock reaction depends heavily on what was already priced — an expected approval creates less upside than a surprise approval where CRL risk was elevated.
Finding PDUFA Dates for 2026
There is no single FDA-published PDUFA calendar. Dates are assembled from: company press releases (required when FDA accepts NDA/BLA), FDA AdCom meeting calendars, 10-K and 10-Q pipeline disclosures, and biotech catalyst aggregators.
The 2026 PDUFA calendar is partially visible now. Drugs with applications accepted in late 2025 under standard 10-month review have PDUFA dates accumulating through 2026. Priority review designations compress timelines to approximately Q2 2026 for drugs accepted in Q4 2025.
Evaluating a PDUFA Setup
Not all PDUFA dates are tradeable. Key evaluation inputs:
- AdCom vote result — the single highest-weight input
- Phase 3 data strength — primary endpoint clarity, p-values, safety profile
- Prior FDA communications — prior CRLs, clinical holds, special protocol assessments
- Implied probability vs. your probability — options pricing implies market probability; a differentiated view is the edge
- Downside scenario — how much market cap is at risk on a CRL?
Keeping a current PDUFA calendar across dozens of names requires continuous monitoring of company filings, FDA announcements, and press releases. BiotechSigns maintains a live PDUFA and biotech catalyst calendar with the underlying clinical data context — so you are tracking the data quality behind each decision, not just the date.
Frequently Asked Questions
What happens if the FDA misses a PDUFA date?
The FDA can extend its review by 3 months if it receives new information from the applicant late in the review cycle. Companies must disclose this via 8-K. Extensions are moderately negative signals — they introduce uncertainty — but are not inherently predictive of a CRL.
How reliable are AdCom votes as approval predictors?
The FDA has followed AdCom recommendations roughly 75-80% of the time historically. Strong positive votes (14-1 or 15-0) are highly predictive. Close votes (8-7) leave significant uncertainty. The FDA occasionally overrides negative votes for drugs with compelling unmet need — uncommon but not unprecedented.
What is Priority Review and how does it affect trading timelines?
Priority Review shortens the standard 10-month window to 6 months for drugs offering significant improvement over existing therapies for serious conditions. It compresses the catalyst sequence and can increase stock appreciation prior to the decision date, but does not change approval probability.
Can a company resubmit after a Complete Response Letter?
Yes. A CRL identifies deficiencies but does not permanently close the application. Resubmission triggers a new 6-month (Class 1) or 12-month (Class 2) review clock. Multiple CRLs on the same drug are a serious negative signal but not always fatal.
Is options trading around PDUFA dates viable?
It is common. Implied volatility typically expands in the weeks before a PDUFA date and collapses immediately after (IV crush). Long options require the move to exceed what the market has priced in. Defined-risk spreads or straddles are more commonly used than outright directional bets by experienced event traders.
This is for informational purposes only. Not financial advice.